
    
      This is an open-label, prospective, multicenter, randomized Phase II, clinical trial
      evaluating the efficacy and safety of Decitabine-Carboplatin combination in recurrent,
      platinum resistant ovarian cancer patients in comparison to physician' choice chemotherapy:

      Arm A: Carboplatin AUC (Area Under Curve) 5 d 8 q 28 Plus Decitabine 10 mg/mq iv d1-5 q 28

      Arm B: Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q
      28 or Weekly Paclitaxel 80 mg/mq gg 1, 8, 15 q 28

      Patients will be randomly assigned in a 1:1 ratio to treatment arms.
    
  